Canadian firm SemBioSys Genetics last week announced that its
proprietary plant-produced insulin has been shown to be
indistinguishable from human insulin, opening up a whole new
potential source of the hormone.
Biotechnology firm Apollo claims to have achieved mission
impossible in the oral delivery of insulin by successfully lowering
blood glucose levels in diabetic rats using its proprietary oral
Silicon-based micro-machined devices for the controlled delivery of
oral therapeutics, developed by Tejal Desai from the University of
California, have won first prize at the 2006 Eurand Award
Programme, impressing with their ability...
Generex has registered a new patent in the US that covers broad
claims for the delivery of macromolecules via the buccal cavity of
the mouth, further safeguarding its RapidMist drug delivery
technology which it uses to spray insulin...
The convenience of non-invasive insulin delivery methods is set to
overcome their high cost and concerns about safety and efficacy,
with the greatest beneficiary being the European inhaled insulin
market which is predicted to swell...
The insulin market is set to explode over the next five years as
uptake of insulin therapy is likely to increase with sufferers
benefiting from heightened awareness and knowledge as well as the
influx of affordable, innovative product...
The insulin delivery devices thriving in today's market will slowly
be replaced as new and better technologies continue to rise from
the R&D pipeline. For current market leader, Novo Nordisk, this
threat is particularly dangerous.